Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2 - 05/10/18
Doi : 10.1016/j.jaci.2018.06.006
Guillaume Churlaud, PharmD, PhD a, b, ∗, Chadi Abbara, PharmD, PhD c, ∗, Pierre-Axel Vinot, MSc a, b, Gwladys Fourcade, PhD b, Paul-Gydeon Ritvo, PhD b, Roberta Lorenzon, MD a, b, Michelle Rosenzwajg, MD, PhD a, b, Bertrand Diquet, PharmD, PhD c, David Klatzmann, MD, PhD a, b 
a AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation- Immunopathology-Biotherapy Department (i2B), Paris, France
b Sorbonne Université, UPMC Univ Paris 06, Immunology-Immunopathology-Immunotherapy (I3), Paris, France
c Service de Pharmacologie, Toxicologie et centre de pharmacovigilance, CHU et faculté de santé, Université d'Angers, Angers, France
| The project was funded by the LabEx Transimmunom (grant no. ANR-11-IDEX-0004-02) and European Research Council Advanced Grant TRiPoD (322856) to D.K. G.C. was supported by the Académie Nationale de Médecine. |
|
| Disclosure of potential conflict of interest: M. Rosenzwajg and D. Klatzmann are inventors in a patent application related to the therapeutic use of ld-IL2 for treating autoimmune-related or inflammatory disorders, which belongs to their academic institutions and has been licensed to ILTOO pharma. G. Churlaud, M. Rosenzwajg, and D. Klatzmann hold shares in ILTOO pharma. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 4
P. 1344 - octobre 2018 Retour au numéro
Article précédent
- IL-33 induces functional CCR7 expression in human mast cells
- Maiko Emi-Sugie, Sumika Toyama, Akio Matsuda, Hirohisa Saito, Kenji Matsumoto
- On a Western diet, APOE ?4 is associated with low innate immune sensing, but not APOE ?3
- Janina Dose, Anke Schloesser, Guillermo G. Torres, Geetha Venkatesh, Robert Häsler, Friederike Flachsbart, Wolfgang Lieb, Almut Nebel, Gerald Rimbach, Patricia Huebbe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?